Stock comparison
Boston Scientific
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BSX
Boston Scientific
Market cap
$85.88B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Boston Scientific BSX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BSX | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 70B | HAE |
| Benjamin Graham | 69B | 85A | HAE |
| Philip Fisher |
Side-by-side metrics
| Metric | BSX | HAE |
|---|---|---|
| Market cap | $85.88B | $2.98B |
| P/E (TTM) | 22.0x | 24.8x |
| EV/EBIT | 22.1x | 14.1x |
| ROIC (TTM) | 9.9% | 8.37% |
| Gross margin | 70.41% | 55.74% |
| Net margin | 17.24% | 7.29% |
| Revenue CAGR 5y | 13.99% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BSX leads on
- Market cap$85.88Bvs $2.98B+97%
- Debt / Equity0.4xvs 1.5x+72%
- Net margin17.24%vs 7.29%+58%
- Revenue CAGR 5y13.99%vs 7.65%
More like HAE
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.